Skip to main navigation
Galectin Therapeutics Logo
  • Blog
  • What We Do
    • Galectin Proteins
    • Develop Proprietary Compounds
    • Discovery Programs
    • Intellectual Property
  • Our Pipeline
    • Pipeline Overview
    • Development Programs
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Special Consultants
    • Careers
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
    • Email Alert Subscription
  • Learn More
    • About Belapectin
    • About Galectin-3
    • About the NAVIGATE Study
    • Resources
    • Video Library
    • Publications
    • News
  • Contact Us
  • What We Do
    • Galectin Proteins
    • Develop Proprietary Compounds
    • Discovery Programs
    • Intellectual Property
  • Our Pipeline
    • Pipeline Overview
    • Development Programs
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Special Consultants
    • Careers
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
    • Email Alert Subscription
  • Learn More
    • About Belapectin
    • About Galectin-3
    • About the NAVIGATE Study
    • Resources
    • Video Library
    • Publications
    • News
  • Contact Us
SEC Filings

Investor Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • Special Consultants
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock Information
    • Analyst Coverage
  • FAQs
  • Email Alert Subscription

SEC Filing Details

Document Details

Form
8-K
Filing Date
Jan 5, 2023
Document Date
Jan 5, 2023
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Galectin Therapeutics Inc.
Issuer
GALECTIN THERAPEUTICS INC

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
XML - XBRL INSTANCE DOCUMENT
Galectin Therapeutics Logo - Footer

© 2023 Galectin Therapeutics Inc. – All Rights Reserved

  • Compassionate Use Policy
  • Privacy Policy
  • Terms of Use
  • Sitemap

Disclaimer: This site may contain forward-looking information.